Sentences with phrase «precision cancer therapy»
If these results are validated in subsequent testing, in the future an oncologist will have many more options for precision cancer therapy.»
https://www.sciencedaily.com/ Not exact matches
Matching unique genetic information from cancer patients» tumors with treatment options — an emerging area of precision medicine efforts — often fails to identify all patients who may respond to certain therapies.
«Such advances in sequencing technology facilitate rational precision therapies for individuals with late - stage cancer.»
This assay will bring the benefits of precision diagnosis and individualized therapy to patients with lymphoid cancer.
The researchers, at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, say their test is the first developed for a precision prostate cancer therapy targeted at specific genetic faults within tuCancer Research, London, and The Royal Marsden NHS Foundation Trust, say their test is the first developed for a precision prostate cancer therapy targeted at specific genetic faults within tucancer therapy targeted at specific genetic faults within tumours.
«Researchers ID cancer gene - drug combinations ripe for precision medicine: Yeast, human cells and bioinformatics help develop one - two punch approach to personalized cancer therapy.»
The process, which located a genetic site for the most common form of prostate cancer, has potential for developing precision therapy for other cancers, such as breast, brain and colorectal, say researchers at The University of Texas MD Anderson Cancer Ccancer, has potential for developing precision therapy for other cancers, such as breast, brain and colorectal, say researchers at The University of Texas MD Anderson Cancer CCancer Center.
The new findings could be used to inform precision - medicine approaches that help minimize a person's risk for common diseases — such as diabetes, cardiovascular disease and cancer — by tailoring diet - based prevention and therapy to the specific needs of an individual.
Wolff believes that newer, precision medicine therapies will ultimately help his patients, particularly the 10 percent or so whose cancer is more driven by heredity than way of life.
This new knowledge is also making precision medicine a reality by enabling the development of highly targeted therapies that offer the potential for improved treatment outcomes, especially for patients battling cancer.
Other biomarkers and genetic signatures are being used in an effort to predict the aggressiveness of an individual patient's prostate cancer, «but the current information doesn't make it possible for their gene signature to be an actual target for precision medicine targeted therapy,» Ellis explained.
«In identifying a specific abnormality in a patient's cancer instead of the overall organ where it first presented, the opportunity exists to provide tailored therapies for patients,» notes Lorna Rodriguez, MD, PhD, director of the precision medicine initiative at the Cancer Institute and professor of obstetrics, gynecology and reproductive sciences at Robert Wood Johnson Medical Scancer instead of the overall organ where it first presented, the opportunity exists to provide tailored therapies for patients,» notes Lorna Rodriguez, MD, PhD, director of the precision medicine initiative at the Cancer Institute and professor of obstetrics, gynecology and reproductive sciences at Robert Wood Johnson Medical SCancer Institute and professor of obstetrics, gynecology and reproductive sciences at Robert Wood Johnson Medical School.
«This platform has tremendous potential to advance precision oncology, where we can use a patient's tumor DNA to really tailor therapy, but we have to be really rigorous about the science of developing the platform,» agrees Carol Bult, director of the PDX / Cancer Avatar Program at the Jackson Laboratory.
We provide access to the latest medicines and technology, as well as the most advanced clinical trials including novel personalized targeted therapies including precision medicine and immunotherapy - some that are only offered at NCI - designated Comprehensive Cancer Centers like ours.
Affigen, LLC — The Company uses «precision design» to develop tumor identifying therapies to treat cancer.
NCI has launched a series of precision medicine clinical trials since 2014, many genetically targeted therapies are currently available to cancer patients, and many more are expected to become available in the near future.
The tests are based on research conducted by Columbia University Irving Medical Center (CUIMC) investigators — and could pave the way for a more precise approach to cancer therapy and help find effective drugs when conventional approaches to precision medicine have failed.
Current precision medicine approaches aim to disable those mutated genes, and many cancer patients today have their tumors analyzed for mutated genes that can be treated with available targeted therapies.
In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests and technologies for various cancer therapies, helping to realize the promise of precision oncology.
The Center for Cancer Targeted Therapies (C2T2) integrates a phase I - Ib / early clinical trials program, a precision cancer medicine infrastructure with expertise on tumor tissue - based state - of - the - art molecular methods, and a core resource with novel non-invasive functional imaging meCancer Targeted Therapies (C2T2) integrates a phase I - Ib / early clinical trials program, a precision cancer medicine infrastructure with expertise on tumor tissue - based state - of - the - art molecular methods, and a core resource with novel non-invasive functional imaging mecancer medicine infrastructure with expertise on tumor tissue - based state - of - the - art molecular methods, and a core resource with novel non-invasive functional imaging methods.
National Cancer Institute and ECOG - ACRIN announce the July 2015 opening of the NCI - MATCH / EAY131 trial, a multi-arm phase II precision medicine study that seeks to determine whether targeted therapies for people whose tumors have specific gene mutations will be effective regardless of cancerCancer Institute and ECOG - ACRIN announce the July 2015 opening of the NCI - MATCH / EAY131 trial, a multi-arm phase II precision medicine study that seeks to determine whether targeted therapies for people whose tumors have specific gene mutations will be effective regardless of cancercancer type.